Skip to main content
Journal cover image

Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.

Publication ,  Journal Article
Cunningham, CK; Chaix, M-L; Rekacewicz, C; Britto, P; Rouzioux, C; Gelber, RD; Dorenbaum, A; Delfraissy, JF; Bazin, B; Mofenson, L; Sullivan, JL
Published in: J Infect Dis
July 15, 2002

Pediatric AIDS Clinical Trials Group protocol 316 was an international, multicenter, placebo-controlled trial comparing single-dose oral nevirapine (200 mg to mother and 2 mg/kg to infant) with placebo in human immunodeficiency virus (HIV)-infected pregnant women receiving standard antiretroviral therapy. This substudy evaluated the emergence of nevirapine-resistance mutations at 6 weeks postpartum in a subgroup of participants. Maternal risk factors for the emergence of nevirapine-resistance mutations were evaluated. Mutations associated with nevirapine resistance were detectable at delivery, prior to receipt of study drug, in 5 (2.3%) of 217 women. Fourteen (15%; 95% confidence interval, 8%-23%) of 95 women who received intrapartum nevirapine developed a nevirapine-resistance mutation 6 weeks postpartum. The most common mutation was K103N, which was present in 10 women. The risk for development of a new nevirapine-resistance mutation did not correlate with CD4 cell count or HIV-1 RNA load at delivery or with type of antepartum antiretroviral therapy. The risk of nevirapine resistance should be considered when determining the risks or benefits of intrapartum nevirapine in women receiving antepartum antiretroviral therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

July 15, 2002

Volume

186

Issue

2

Start / End Page

181 / 188

Location

United States

Related Subject Headings

  • Reverse Transcriptase Polymerase Chain Reaction
  • RNA, Viral
  • Pregnancy Complications, Infectious
  • Pregnancy
  • Postpartum Period
  • Phylogeny
  • Nevirapine
  • Mutation
  • Molecular Sequence Data
  • Microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cunningham, C. K., Chaix, M.-L., Rekacewicz, C., Britto, P., Rouzioux, C., Gelber, R. D., … Sullivan, J. L. (2002). Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis, 186(2), 181–188. https://doi.org/10.1086/341300
Cunningham, Coleen K., Marie-Laure Chaix, Claire Rekacewicz, Paula Britto, Christine Rouzioux, Richard D. Gelber, Alejandro Dorenbaum, et al. “Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.J Infect Dis 186, no. 2 (July 15, 2002): 181–88. https://doi.org/10.1086/341300.
Cunningham CK, Chaix M-L, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002 Jul 15;186(2):181–188.
Journal cover image

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

July 15, 2002

Volume

186

Issue

2

Start / End Page

181 / 188

Location

United States

Related Subject Headings

  • Reverse Transcriptase Polymerase Chain Reaction
  • RNA, Viral
  • Pregnancy Complications, Infectious
  • Pregnancy
  • Postpartum Period
  • Phylogeny
  • Nevirapine
  • Mutation
  • Molecular Sequence Data
  • Microbiology